IFRX
Price
$0.86
Change
+$0.03 (+3.61%)
Updated
Aug 15 closing price
Capitalization
58.46M
73 days until earnings call
NMRA
Price
$1.63
Change
+$0.05 (+3.16%)
Updated
Aug 15 closing price
Capitalization
263.97M
72 days until earnings call
Interact to see
Advertisement

IFRX vs NMRA

Header iconIFRX vs NMRA Comparison
Open Charts IFRX vs NMRABanner chart's image
InflaRx
Price$0.86
Change+$0.03 (+3.61%)
Volume$197.88K
Capitalization58.46M
Neumora Therapeutics
Price$1.63
Change+$0.05 (+3.16%)
Volume$888.9K
Capitalization263.97M
IFRX vs NMRA Comparison Chart in %
Loading...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NMRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IFRX vs. NMRA commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFRX is a Hold and NMRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (IFRX: $0.86 vs. NMRA: $1.63)
Brand notoriety: IFRX and NMRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IFRX: 65% vs. NMRA: 54%
Market capitalization -- IFRX: $58.46M vs. NMRA: $263.97M
IFRX [@Biotechnology] is valued at $58.46M. NMRA’s [@Biotechnology] market capitalization is $263.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IFRX’s FA Score shows that 0 FA rating(s) are green whileNMRA’s FA Score has 1 green FA rating(s).

  • IFRX’s FA Score: 0 green, 5 red.
  • NMRA’s FA Score: 1 green, 4 red.
According to our system of comparison, NMRA is a better buy in the long-term than IFRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IFRX’s TA Score shows that 6 TA indicator(s) are bullish while NMRA’s TA Score has 4 bullish TA indicator(s).

  • IFRX’s TA Score: 6 bullish, 3 bearish.
  • NMRA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, IFRX is a better buy in the short-term than NMRA.

Price Growth

IFRX (@Biotechnology) experienced а +7.84% price change this week, while NMRA (@Biotechnology) price change was +11.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

IFRX is expected to report earnings on Oct 30, 2025.

NMRA is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NMRA($264M) has a higher market cap than IFRX($58.5M). IFRX YTD gains are higher at: -65.065 vs. NMRA (-84.623). IFRX has higher annual earnings (EBITDA): -44.22M vs. NMRA (-273.7M). NMRA has more cash in the bank: 249M vs. IFRX (65.9M). IFRX has less debt than NMRA: IFRX (703K) vs NMRA (938K). IFRX has higher revenues than NMRA: IFRX (130K) vs NMRA (0).
IFRXNMRAIFRX / NMRA
Capitalization58.5M264M22%
EBITDA-44.22M-273.7M16%
Gain YTD-65.065-84.62377%
P/E RatioN/AN/A-
Revenue130K0-
Total Cash65.9M249M26%
Total Debt703K938K75%
FUNDAMENTALS RATINGS
IFRX: Fundamental Ratings
IFRX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IFRXNMRA
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
88%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 8 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NMRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLLDY10.150.13
+1.30%
Sanlam Ltd.
GYUAF17.50N/A
N/A
Gs Yuasa Corp.
MSSEL58.89N/A
N/A
Massachusetts Electric Co.
ECLP6.00N/A
N/A
Eclipse Bancorp Inc.
SITKF0.52-0.01
-2.59%
Sitka Gold Corporation

IFRX and

Correlation & Price change

A.I.dvisor tells us that IFRX and RCUS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IFRX and RCUS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
+4.30%
RCUS - IFRX
28%
Poorly correlated
+4.84%
VERA - IFRX
28%
Poorly correlated
+1.27%
NMRA - IFRX
26%
Poorly correlated
+3.16%
ARWR - IFRX
26%
Poorly correlated
+9.21%
FULC - IFRX
26%
Poorly correlated
+3.33%
More

NMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with NGNE. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then NGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NMRA
1D Price
Change %
NMRA100%
+3.16%
NGNE - NMRA
38%
Loosely correlated
+1.53%
ABOS - NMRA
37%
Loosely correlated
+1.43%
AURA - NMRA
36%
Loosely correlated
-4.00%
SNDX - NMRA
35%
Loosely correlated
+6.86%
RCUS - NMRA
34%
Loosely correlated
+4.84%
More